People: Neurobiological Technologies Inc (NTII.PK)

NTII.PK on OTC Markets Group

0.04USD
27 May 2014
Price Change (% chg)

$-0.01 (-18.37%)
Prev Close
$0.05
Open
$0.05
Day's High
$0.05
Day's Low
$0.04
Volume
121,763
Avg. Vol
13,040
52-wk High
$0.12
52-wk Low
$0.04

Search Stocks

Summary

Name Age Since Current Position

Matthew Loar

49 2010 Acting Chief Executive and Financial Officer, Director

William Fletcher

65 2009 Director

John Stuppin

79 1994 Director

Biographies

Name Description

Matthew Loar

Mr. Matthew M. Loar serves as Acting Chief Executive and Financial Officer, Director of Neurobiological Technologies, Inc., since December 2010. He has served as Director of the Company, since December 2009. He previously served as Vice President and Chief Financial Officer of the Company from April 2008 to December 2009, when Mr. Loar’s employment with the Company was terminated following the Company’s filing for dissolution. Mr. Loar is licensed in California as a Certified Ppublic Accountant and has over 20 years of financial management experience. Mr. Loar joined the Company from Osteologix, Inc., where he served as Chief Financial Officer from September 2006 to April 2008. Prior to his tenure at Osteologix, Mr. Loar was Chief Financial Officer of Genelabs Technologies, Inc. beginning in 2001. Prior to being appointed CFO at Genelabs, Mr. Loar was Vice President, Finance and Controller for approximately six years. Earlier, Mr. Loar held finance positions with an international manufacturing company and was audit manager with a public accounting firm. Mr. Loar holds a B.A. degree from the University of California, Berkeley.

William Fletcher

Mr. William A. Fletcher serves as Director of Neurobiological Technologies, Inc., since December 2009. He has served as a Director of the Company since February 21, 2007. Mr. Fletcher also served as Acting Chief Executive Officer of the Compnay, from January 2009 through December 2009. Mr. Fletcher was Chairman of Teva Pharmaceuticals North America from December 2004 until September 2010. Prior to being appointed Chairman, he was President and Chief Executive Officer of Teva’s North American activities, where he started employment in 1985. Mr. Fletcher served as Vice President, Sales and Marketing of the Pennsylvania-based Lemmon Company (1980 to 1983) and then as President (1983-1985) following the company’s acquisition by Teva and WR Grace. Prior to 1980, Mr. Fletcher was Business Development Manager and International Marketing Manager of Synthelabo, a pharmaceutical subsidiary of L’Oreal in Paris. From 1970 to 1977 he served in various international sales and marketing positions for Hoffman-LaRoche. Mr. Fletcher graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969.

John Stuppin

Mr. John B. Stuppin serves as Director of Neurobiological Technologies, Inc., since July 1994. He is a founder of the Company and has served as a Director of the Company since September 1988. From September 1987 until October 1990, Mr. Stuppin served as President of the Company, from November 1990 to August 1993 as co-chairman of the Board of Directors, from October 1990 until September 1991 as Executive Vice President, and from April 1991 until July 1994 as Treasurer. He also served as the acting Chief Financial Officer of the Company from the Company’s inception through December 1993 and served as a part-time employee of the Company in a business development capacity from December 1990 to December 2005. Mr. Stuppin is an investment banker and a venture capitalist. He has over 40 years’ experience in the start up and management of companies active in emerging technologies and has been the president of a manufacturing company. He is chairman of the board of Energy Focus, Inc. Mr. Stuppin holds an A.B. degree from Columbia University.

Basic Compensation

Name Fiscal Year Total

Matthew Loar

345,773

William Fletcher

153,975

John Stuppin

--
As Of 29 Jun 2010

Options Compensation

Name Options Value

Matthew Loar

0 0

William Fletcher

15,000 3,900

John Stuppin

15,000 3,900
Search Stocks